MedTrace Logo

Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases

NCT06405256 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-05-08

No results posted yet for this study

Summary

This study is an ambispective cohort study to evaluate the displacement and deformation of large brain metastases (BM) treated with magnetic resonance imaging-guided adaptive radiotherapy (MRIgART)

Conditions

Interventions

RADIATION

magnetic resonance imaging-guided adaptive radiotherapy

Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Nan Bi, MD · Chinese Academy of Medical Sciences and Peking Union Medical College

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-03
Primary Completion
2025-03-18
Completion
2025-03-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06405256 on ClinicalTrials.gov